Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Also known as:WIPF1 Wiskott-Aldrich syndromeWiskott-Aldrich syndrome caused by mutation in WIPF1Wiskott-Aldrich syndrome type 2
Overview
Any Wiskott-Aldrich syndrome in which the cause of the disease is a mutation in the WIPF1 gene.
GeneticsAutosomal recessive · WIPF1 (chr 2)
Clinical Presentation
Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.
Features include always present findings: Abnormal natural killer cell physiology, Recurrent infections, Eczematoid dermatitis, and Abnormal T cell proliferation and others.
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
No clinical trials have been registered for Wiskott-Aldrich syndrome 2.
71 publications have been identified in PubMed for Wiskott-Aldrich syndrome 2. Research spans Basic Science / Preclinical (51%), Review / Meta-Analysis (13%), and Epidemiology / Natural History (13%).
Research Type
Count
% of Total
Laboratory research
36
51%
Data assembled from 6 of 12 sources · Last updated Nov 3, 2026, 11:47 PM UTC
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
→Should my partner and I meet with a genetic counselor to discuss carrier status and family planning?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?
FAQ
Frequently Asked Questions
Common questions about Wiskott-Aldrich syndrome 2
Wiskott-Aldrich syndrome 2 is a condition caused by mutations in the WIPF1 gene that affects the immune system. Individuals with this condition typically present with abnormalities in immune function, as highlighted by their susceptibility to recurrent infections and skin issues. It is inherited in an autosomal recessive manner, meaning both copies of the gene must be altered for the condition to manifest. Precise prevalence data is not available, and as such, its occurrence in the population is not well established.
The clinical presentation of Wiskott-Aldrich syndrome 2 is marked by a consistent set of immune-related features. Affected individuals almost always exhibit abnormal natural killer cell physiology, recurrent infections, and eczematoid dermatitis. In addition, abnormal T cell proliferation, thrombocytopenia, and a decreased proportion of CD8+ T cells are universally observed. Not all individuals experience all features to the same degree, and severity varies considerably between affected persons.
This condition is caused by mutations in the WIPF1 gene, which plays a crucial role in the regulation of the actin cytoskeleton in immune cells. Disruption of this gene's normal function impairs various immune processes, contributing to the characteristic features of the syndrome. Wiskott-Aldrich syndrome 2 is inherited in an autosomal recessive pattern, meaning that an individual needs to inherit two altered copies of the gene—one from each parent—to be affected. Families with a history of the condition are encouraged to seek genetic counseling for further guidance. Associated genes include WIPF1.
Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder. Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder.Magnific Wiskott-Aldrich syndrome is a rare inherited immune disorder affecting boys that causes eczema, immune deficiency, and bleeding. A new study shows that infusing gene-corrected stem cells provides lasting protection for patients. The FDA approved this therapy in December 2025 after citing a 93% drop in severe infections. Analysis of where the gene landed in the DNA showed blood production drawn from many different corrected cells, with no sign that the virus had disturbed cancer genes. The treatment still carries risks. Nineteen patients experienced serious adverse events. Most were infections. The study had no control group, which the authors note is inevitable in an ultra-rare disease. The FDA requires a · 15-year follow-up study to track secondary cancer risk. The path to approval is also unusual. The therapy began at an academic center, passed through pharmaceutical development and returned to Fondazione Telethon, an Italian nonprofit organization, which secured approval in Europe and the U.S. The FDA describes it as the first cell and gene therapy approved by a nonprofit applicant. A durable treatment raises the stakes for early diagnosis. In this study, symptoms started at a median age of about four months, and diagnosis followed at a median age of one year. Genetic testing of mothers in affected families, and · genome sequencing at birth, can identify boys with the disease before the first serious infection. The lesson of this study reaches beyond one rare disease.
Fondazione Telethon for Waskyra™, ... disorder and the first approved gene therapy developed by a nonprofit organization. Omeros for YARTEMLEA®, the first and only FDA-approved treatment for adults and children 2 years and older with hematopoietic stem cell ... Fondazione Telethon for Waskyra™, a breakthrough gene therapy for Wiskott-Aldrich syndrome (WAS) that represents the first FDA-approved gene therapy for a primary immunodeficiency disorder and the first approved gene therapy developed by a nonprofit organization. Omeros for YARTEMLEA®, the first and only FDA-approved treatment for adults and children 2 years and older with hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA), a significant and often fatal complication of stem cell transplantation. Their progress in addressing the unique challenges of these conditions is also contributing knowledge, approaches, and breakthroughs that help move science and the entire rare disease field forward." ... Mighty Therapeutics for FORZINITY™, the first therapy for Barth syndrome — a very rare, progressive, and life-limiting genetic disease affecting mitochondria — shown to improve muscle strength and quality of life. Stephen Kingsmore, MD, DSc of California, recipient of a Medical & Scientific Trailblazer Award for founding the Rady Children’s Institute for Genomic Medicine NORD Rare Disease Center of Excellence, where he pioneered whole genome sequencing, rapid genetic testing as a clinical tool, and the first comprehensive genomic carrier screening test. Mark Skinner, JD of New York, recipient of the Lifetime Achievement Award for his advocacy for bleeding disorders in New York, the U.S., and worldwide through the World Federation of Hemophilia, the National Bleeding Disorders Foundation, the HHS Advisory Committee on Blood and Tissue Safety and Availability, and NORD's Board of Directors. View original content to download multimedia:https://www.prnewswire.com/news-releases/nord-announces-the-2026-rare-impact-award-honorees-advancing-innovation-research-and-advocacy-for-rare-diseases-302889723.html · SOURCE National Organization for Rare Disorders (NORD®) ... Jazz Pharmaceuticals, Inc. Omeros Corporation ... Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder ... Get daily news updates when you subscribe to GenePool!
Recent research highlights large vessel vasculopathy as an underrecognized complication in Wiskott-Aldrich syndrome. This discovery may prompt further investigation into the cardiovascular risks associated with this rare genetic disorder.
